Iovance Biotherapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Iovance Biotherapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Iovance Biotherapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Iovance Biotherapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Iovance Biotherapeutics Inc (Iovance) is a biopharmaceutical company. It focuses on the development and commercialization of novel immunotherapy products for treating various cancers. The company develops products based on its tumour-infiltratin lymphocyte (TIL) technology. Iovance's major products include Amtagvi (lifileucel), an autologous, ready-to-infuse cell therapy indicated for the treatment of melanoma and metastatic cervical cancer, and Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen. The company's products are primarily used for treating adult patients with unresectable or metastatic melanoma. It operates a manufacturing facility in Philadelphia and a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.
Headquarters
United States of America
Address
Suite 100, 825 Industrial Road, San Carlos, California, 94070
Website
www.iovance.com
Telephone
1 302 6974590
No of Employees
975
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IOVA (NASD)
Revenue (2024)
$263.5M
60.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-5.1%
(2024 vs 2023)
Market Cap*
$1.8B
Net Profit Margin (2024)
XYZ
34.6%
(2024 vs 2023)
* As of and is in US$
Iovance Biotherapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed | Amtagvi |
| Amtagvi (lifileucel) - T cell therapy | Proleukin |
| Proleukin (aldesleukin) - T cell activity | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In September, the company selected InspiroGene by McKesson as specialty pharmacy partner for Amtagvi (lifileucel) to expand access for patients with advanced melanoma. |
| 2025 | Regulatory Approval | In August, the company received approval for Amtagvi from Health Canada. |
| 2024 | Regulatory Approval | In June, the company submitted an application to the European Medicines Agency for lifileucel, a TIL cell therapy, for the treatment of adult patients with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. |
Competitor Comparison
| Key Parameters | Iovance Biotherapeutics Inc | Merck & Co Inc | AstraZeneca Plc | Sanofi | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | France | United States of America |
| City | San Carlos | Rahway | Cambridge | Paris | Princeton |
| State/Province | California | New Jersey | Cambridgeshire | Ile-de-France | New Jersey |
| No. of Employees | 975 | 75,000 | 96,100 | 76,493 | 32,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Iain Dukes, Ph.D. | Chairman | Executive Board | 2016 | 67 |
| Frederick G. Vogt, Ph.D. | General Counsel; President; Interim Chief Executive Officer; Director | Executive Board | 2021 | 52 |
| Corleen Roche | Chief Financial Officer | Senior Management | 2025 | 60 |
| Igor Bilinsky, Ph.D. | Chief Operating Officer | Senior Management | 2021 | 53 |
| Friedrich Graf Finckenstein, M.D. | Chief Medical Officer | Senior Management | 2019 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer